News | March 18, 2026
Zydus, Lupin join forces to expand access to semaglutide in India
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
This study demonstrates the power of real-time glucose information for people with Type 2 diabetes treated with basal insulin
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
Giredestrant shows promise despite missing primary goal
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
Their findings, published in the journal Nature, reveal that the spines’ unique porous internal structure allows them to convert water movement into measurable electrical signals
Subscribe To Our Newsletter & Stay Updated
